Mechanisms of resistance to targeted therapy in cancer
Pro Research Analysisby 
Searched over 200M research papers
Genetic and Molecular Target Alterations in Cancer Therapy Resistance
One of the main mechanisms of resistance to targeted therapy in cancer is the alteration of the molecular targets themselves. Tumor cells can acquire secondary mutations in the target gene, such as kinase domain mutations, which reduce the effectiveness of drugs designed to inhibit these targets. This is commonly seen in non-small cell lung cancer (NSCLC) with mutations in genes like EGFR, ALK, and ROS1, where secondary mutations or gene fusions can lead to resistance against tyrosine kinase inhibitors (TKIs) Xiang2024McCoach2018Wu2022. Additionally, gene amplification and copy number variations in proto-oncogenes can also contribute to resistance by increasing the expression of the target or activating alternative oncogenic pathways McCoach2018Wu2022.
Activation of Bypass Signaling Pathways and Tumor Cell Plasticity
Cancer cells can activate alternative signaling pathways to bypass the inhibited target, maintaining their growth and survival despite therapy. For example, activation of HER2-mediated signaling, EGFR, KRAS, and other pathways has been observed in resistant tumors McCoach2018Wu2022. Tumor cell plasticity, including phenotypic switching and epithelial-to-mesenchymal transition (EMT), allows cancer cells to adapt to targeted therapies and evade drug effects. This plasticity is often driven by both genetic and non-genetic mechanisms, such as epigenetic modifications and changes in transcription factor activity Lei2023Shi2023.
Tumor Heterogeneity and Minimal Residual Disease
Intratumoral heterogeneity, where different subpopulations of tumor cells harbor distinct genetic or epigenetic profiles, is a key driver of resistance. Some cells may survive initial therapy (minimal residual disease) and later acquire additional mutations, leading to tumor relapse and resistance Xiang2024Lim2019. This heterogeneity complicates treatment, as targeting one driver mutation may not eliminate all resistant subclones within the tumor .
Tumor Microenvironment and Immune Evasion
The tumor microenvironment (TME) plays a significant role in resistance to targeted therapies. Changes in the TME, such as increased immunosuppression or altered interactions between tumor and immune cells, can promote resistance. Tumors may also evade immune detection by modulating immune checkpoints or suppressing immune cell activity, reducing the effectiveness of immunotherapies and targeted agents Xiang2024Lei2023.
Drug Efflux, Metabolic Changes, and DNA Repair
Other mechanisms include increased drug efflux through transporter proteins, altered drug metabolism, enhanced DNA repair capacity, and suppression of cell death pathways (apoptosis). These changes can reduce the intracellular concentration of drugs or allow cancer cells to survive DNA damage induced by therapy Lackner2012Mansoori2017.
Epigenetic Modifications and Key Regulators
Epigenetic changes, such as DNA methylation and histone modification, can alter gene expression and contribute to resistance. For instance, overexpression of EZH2, a histone methyltransferase, has been linked to drug resistance in breast cancer and other malignancies, making it a potential therapeutic target Lackner2012Chen2024Shi2023.
Strategies to Overcome Resistance
To address resistance, several strategies are being explored:
- Combination therapies targeting multiple pathways or mechanisms simultaneously Xiang2024Sarmento-Ribeiro2019Lei2023.
- Identification and use of predictive biomarkers to tailor therapy and monitor resistance Sarmento-Ribeiro2019Lei2023.
- Modulation of the tumor microenvironment to enhance drug response Xiang2024Lei2023.
- Development of new drugs targeting resistance mechanisms, including epigenetic regulators and cell plasticity pathways Lei2023Chen2024Shi2023.
- Advanced diagnostic tools, such as liquid biopsy and single-cell sequencing, to detect emerging resistance early and guide treatment adjustments .
Conclusion
Resistance to targeted cancer therapies is a complex, multifactorial process involving genetic mutations, activation of alternative pathways, tumor heterogeneity, microenvironmental changes, and epigenetic modifications. Understanding these mechanisms is crucial for developing effective strategies to overcome resistance and improve patient outcomes. Ongoing research into combination therapies, biomarker identification, and novel drug targets holds promise for the future management of drug-resistant cancers Xiang2024Lackner2012Sarmento-Ribeiro2019+7 MORE.
Sources and full results
Most relevant research papers on this topic